Stock Analysis, Dividends, Split History

CBIS / Cannabis Science, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.07
Volume33,704,700.00
Market Cap ($M)181.18
Enterprise Value ($M)180.60
Book Value ($M)-2.61
Book Value / Share-0.00
Price / Book-69.44
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Preferred Stock Shares Outstanding 1,000,000
Common Shares Outstanding 2,350,355,296
Common Shares Outstanding2 2,466,805,296
Common Stock Shares Outstanding 2,350,355,296
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)8.53
Return on Assets (ROA)-5.66
Return on Equity (ROE)4.85
Balance Sheet (mrq) ($M)
Assets2.08
Liabilities4.69
Quick Ratio0.06
Current Ratio0.09
Income Statement (mra) ($M)
Revenues9,263.00
Operating Income-8.72
Net Income-10.20
Earnings Per Share Basic And Diluted-0.01
Cash Flow Statement (mra) ($M)
Cash From Operations-1.69
Cash from Investing-0.01
Cash from Financing-0.01
Identifiers and Descriptors
CUSIP137648101
Central Index Key (CIK)1024626

Split History

Stock splits are used by Cannabis Science, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
CBIS : Cannabis Science Stock Analysis and Research Report

2017-11-23 - Asif

Business Overview Cannabis Science, Inc. (formerly Gulf Onshore, Inc.) (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc. Cannabis Science, Inc. is at the forefront of medical cannabis research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In summary, Cannabis Science is dedicated to the creation of cannabis-based...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

AmeriCann CEO to Present at Science and Education Conference in Massachusetts

5h accesswire
DENVER, CO / ACCESSWIRE / September 21, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that CEO Tim Keogh will be speaking at the Cannabis Community Care and Research Network's (C3RN) Cannabis Science and Education Series on Sunday, September 23 in Boston, MA. (2-0)

4 Top Marijuana Penny Stocks for the Rest of 2018

2018-09-06 investorplace
While it’s open to debate whether President Donald Trump made America great, the 2016 election did produce one undeniable result: it laid the foundation for cannabis-related businesses, thereby dramatically improving profitability potential for marijuana penny stocks. (9-3)

Americann Partnership with C3RN Commences Cannabis Research In Massachusetts

2018-07-09 accesswire
DENVER, CO / ACCESSWIRE / July 9, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an agricultural-technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that it is leading a research pilot study in Massachusetts. The research is led by Cannabis Community Care and Research Network (C3RN) in collaboration with UMass Dartmouth. (2-1)

Americann CEO to Present at Science and Education Conference in Massachusetts

2018-06-28 accesswire
DENVER, CO / ACCESSWIRE / June 28, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that CEO Tim Keogh will be speaking at Cannabis Community Care and Research Network's (C3RN) Cannabis Science and Education Series on Thursday, June 28 in Worcester, MA. (9-0)

AmeriCann Partners with C3RN to Conduct Scientific Cannabis Research in Massachusetts

2018-06-20 accesswire
DENVER, CO / ACCESSWIRE / June 20, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that it is formally partnering with Cannabis Community Care and Research Network (C3RN), a Massachusetts-based public benefit corporation focused on cannabis research and technology. (9-0)

CUSIP: 137648101